Children, adults produce different antibodies against Covid-19: Study

Children and adults produce different types of antibodies in response to the novel coronavirus, according to a study which suggests the course of infection and immune response is distinct in kids

Coronavirus, covid, tests
Press Trust of India New York
3 min read Last Updated : Nov 06 2020 | 6:28 PM IST

Children and adults produce different types and amounts of antibodies in response to the novel coronavirus infection, according to a study which suggests the course of the infection and immune response is distinct in kids, and most of them easily clear the virus from their bodies.

"Our study provides an in-depth examination of SARS-CoV-2 antibodies in kids, revealing a stark contrast with adults," said Donna Farber, an immunologist at Columbia University in the US.

Matteo Porotto, associate professor at Columbia University said the infectious course in children is much shorter and probably not as disseminated as in adults.

"Kids may clear this virus more efficiently than adults and they may not need a strong antibody immune response to get rid of it," said Poroto, who co-led the study published on Thursday in the journal Nature Immunology.

Among the 47 children in the study, 16 were treated at Columbia University for Multisystem inflammatory syndrome in children (MIS-C) and 31 kids of similar ages had tested positive for the virus after visiting the medical center for the treatment of other conditions. Half of the children without MIS-C had no COVID-19 symptoms.

The 32 adults in the study ranged from severely affected patients admitted to the hospital to those with milder disease who recovered at home, the researchers said.

Both groups of children produced the same antibody profile, the study found, which differed from that of adults.

Compared with adults, children produced fewer antibodies against the virus's spike protein -- which the virus uses to infect human cells, according to the researchers.

The children's antibodies had the least neutralising activity, while all adults, including young adults in their 20s, produced neutralising antibodies. The sickest adults had the most neutralising activity, they said.

Though it may seem counterintuitive that the sickest patients produce antibodies with the greatest neutralising activity, Farber said that likely reflects the amount of time the virus is present in the sickest patients.

"There is a connection between the magnitude of your immune response and the magnitude of the infection: The more severe the infection, the more robust the immune response, because you need to have more immune cells and immune reactions to clear a higher dose of a pathogen," he added.

In contrast to adults, children also produced very few antibodies against a viral protein that is only visible to the immune system after the virus infects human cells, the researchers said.

"That suggests that in kids, the infection doesn't really spread a lot and doesn't kill a lot of their cells," Farber said.

"Because children clear the natural virus rapidly, they do not have a widespread infection and they do not need a strong antibody response," Porotto added.

The reduced course of infection in children may signify that they are infectious for a shorter period of time compared with adults and therefore less likely to spread the virus, although the researchers did not measure viral load in the children.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusMedical Research

First Published: Nov 06 2020 | 6:26 PM IST

Next Story